Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 16;30(8):103182.
doi: 10.1016/j.jaccas.2024.103182.

TACE With Doxorubicin-Induced Cardiotoxicity

Theo Doyon  1 , Corrado De Marco  2 , Philippe Willems  2 , Giovanni Romanelli  2
Affiliations
Case Reports

TACE With Doxorubicin-Induced Cardiotoxicity

Theo Doyon et al. JACC Case Rep. .

Abstract

Doxorubicin is an effective chemotherapeutic drug used in transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Although very effective, this molecule is known for its potential severe cardiotoxicity, which was the purpose for the development of drug-eluting beads-TACE that showed similar efficacy and improved safety. We present the case of a 58-year-old man with hepatocellular carcinoma who received 5 treatments of conventional TACE with doxorubicin and developed severe cardiotoxicity. Although the cardiotoxic effect of TACE with doxorubicin has already been reported in the literature, this case has serious implications, because the patient had to be removed from the liver transplant waitlist and this development could have been prevented. We believe that this complication of TACE should be more known, and hence more sought out. We also believe that drug-eluting beads-TACE should be preferred because it was proven safer in more frail patients.

Keywords: TACE; anthracycline; cardiotoxicity; doxorubicin; heart failure.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
VISUAL SUMMARY
VISUAL SUMMARY
Timeline for Patient Care
See this image and copyright information in PMC

References

    1. Belger C. Doxorubicin-induced cardiotoxicity and risk factors. Int J Cardiol Heart Vasc. 2023;50 - PMC - PubMed
    1. Sparano J.A., Sahni G. The ESC cardio-oncology guidelines. J Am Coll Cardiol CardioOnc. 2022;5:141–144. - PMC - PubMed
    1. Cho Y., Choi J.W., Kwon H., et al. Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association. Korean J Radiol. 2023;24:606–625. - PMC - PubMed
    1. Vogl T.J., Lammer J., Lencioni R., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V Randomized Trial. AJR Am J Roentgenol. 2011;197:W562–W570. - PubMed
    1. Ma Y., Zhao C., Zhao H., et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res. 2019;11:7456–7470. - PMC - PubMed

Publication types

LinkOut - more resources